The United States of America As Represented by the United States

Ut-battelle, Inc.

Martin Marietta Energy Systems, Inc.

The United States of America As Represented by the Department of Energy

Lockheed Martin Energy Systems, Inc.

Lockheed Martin Energy Research Coirporation

Furn F Knapp, Jr

Saed Mirzadeh

Mark M Goodman

Arnold L Beets

Miting Du

Edward C Lisic

Alvin P Callahan

Prem C Srivastava

Emory D Collins

Rose Ann Boll

Stefan Guhlke

Thomas A Butler

Claude Brihaye

Gilbert Kirsch

A method of producing and purifying promethium-147 including the steps of: irradiating a target material including neodymium-146 with neutrons to produce promethium-147 within the irradiated target material; dissolving the irradiated target material to form an acidic solution; loading the acidic solution onto a chromatographic separation apparatus containing HDEHP; and eluting the apparatus to chromatographically separate the promethium-147 from the neodymium-146.

Chromatographic extraction with di(2-ethylhexyl)orthophosphoric acid for production and purification of promethium-147

A new composition of matter includes Pt characterized by a specific activity of at least 30 mCi/mg Pt, generally made by method that includes the steps of: exposing Ir to a flux of neutrons sufficient to convert a portion of the Ir to Pt to form an irradiated material; dissolving the irradiated material to form an intermediate solution comprising Ir and Pt; and separating the Pt from the Ir by cation exchange chromatography to produce Pt.

High specific activity platinum-195m

A method of preparing high-specific-activity Pt includes the steps of: exposing Ir to a flux of neutrons sufficient to convert a portion of the Ir to Pt to form an irradiated material; dissolving the irradiated material to form an intermediate solution comprising Ir and Pt; and separating the Pt from the Ir by cation exchange chromatography to produce Pt.

Method of preparing high specific activity platinum-195m

A method of separating lutetium from a solution containing Lu and Yb, particularly reactor-produced Lu and Yb, includes the steps of: providing a chromatographic separation apparatus containing LN resin; loading the apparatus with a solution containing Lu and Yb; and eluting the apparatus to chromatographically separate the Lu and the Yb in order to produce high-specific-activity Yb.

Method for preparing high specific activity 177Lu

A .sup.99 Mo/.sup.99m Tc generator system includes a sorbent column loaded with a composition containing .sup.99 Mo. The sorbent column has an effluent end in fluid communication with an anion-exchange column for concentrating .sup.99m Tc eluted from the sorbent column. A method of preparing a concentrated solution of .sup.99m Tc includes the general steps of: a. providing a sorbent column loaded with a composition containing .sup.99 Mo, the sorbent column having an effluent end in fluid communication with an anion-exchange column; b. eluting the sorbent column with a salt solution to elute .sup.99m Tc from the sorbent and to trap and concentrate the eluted .sup.99m Tc on the ion-exchange column; and c. eluting the concentrated .sup.99m Tc from the ion-exchange column with a solution comprising a reductive complexing agent.

Technetium-99m generator system

A method of preparing a concentrated solution of a carrier-free radioisotope which includes the steps of:

Concentration of perrhenate and pertechnetate solutions

A generator system for providing a carrier-free radioisotope in the form of an acid comprises a chromatography column in tandem fluid connection with an ion exchange column, the chromatography column containing a charge of a radioactive parent isotope. The chromatography column, charged with a parent isotope, is eluted with an alkali metal salt solution to generate the radioisotope in the form of an intermediate solution, which is passed through the ion-exchange column to convert the radioisotope to a carrier-free acid form.

Tungsten-188/carrier-free rhenium-188 perrhenic acid generator system

Radiopharmaceuticals useful in brain imaging comprising radiohalogenated thienylethylamine derivatives. The compounds are 5-halo-thiophene-2-isopropyl amines able to cross the blood-brain barrier and be retained for a sufficient length of time to allow the evaluation of regional blood flow by radioimaging of the brain.

Aminopropyl thiophene compounds

Radiopharmaceuticals useful in brain imaging comprising radiohalogenated thienylethylamine derivatives. The compounds are 5-halo-thiophene-2-isopropyl amines able to cross the blood-brain barrier and be retained for a sufficient length of time to allow the evaluation or regional blood flow by radioimaging of the brain.

Radiohalogenated thienylethylamine derivatives for evaluating local

A radioiodinated branched carbohydrate for tissue imaging. Iodine-123 is stabilized in the compound by attaching it to a vinyl functional group that is on the carbohydrate. The compound exhibits good uptake and retention and is promising in the development of radiopharmaceuticals for brain, heart and tumor imaging.

Radioiodinated branched carbohydrates

Radioiodinated glucose analogues for use as imaging agents

A class of radiolabeled compounds to be used in tissue imaging that exhibits rapid brain uptake, good brain:blood radioactivity ratios, and long retention times. The imaging agents are more specifically radioiodinated aromatic amines attached to dihydropyridine carriers, that exhibit heart as well as brain specificity. In addition to the radiolabeled compounds, classes of compounds are also described that are used as precursors and intermediates in the preparation of the imaging agents.

Precursors to radiopharmaceutical agents for tissue imaging

A radiolabeled long chain fatty acid for heart imaging that has dimethyl branching at one of the carbons of the chain which inhibits the extent to which oxidation can occur. The closer to the carboxyl the branching is positioned, the more limited the oxidation, thereby resulting in prolonged retention of the radiolabeled compound in the heart.

Radiolabeled dimethyl branched long chain fatty acid for heart imaging

A generator system to provide iridium-191m for clinical imaging applications comprises an activated carbon adsorbent loaded with a compound containing the parent nuclide, osmium-191. The generator, which has a shelf-life in excess of two weeks and does not require a scavenger column, can be eluted with physiologically compatible saline.

Growing community of inventors

Oak Ridge, TN, United States of America

Furn F Knapp, Jr